Drug-Drug-Induced Akathisia: Two Case Reports.


Journal

Case reports in psychiatry
ISSN: 2090-682X
Titre abrégé: Case Rep Psychiatry
Pays: United States
ID NLM: 101583308

Informations de publication

Date de publication:
2020
Historique:
received: 23 08 2019
revised: 12 02 2020
accepted: 24 03 2020
entrez: 7 5 2020
pubmed: 7 5 2020
medline: 7 5 2020
Statut: epublish

Résumé

Extrapyramidal side effects of psychotropic medicines are usually experienced by patients in the first few weeks of initiating therapy. Patients stabilized on these medications who present with distressing complaints akin to akathisia may be triggered by other factors. This report presents two cases of drug-drug-induced akathisia. Case A is a patient with schizophrenia who was being managed with risperidone 2 mg tablet daily for the past 3 years. She fell ill and reported to a nearby clinic where she was prescribed ciprofloxacin and artemether/lumefantrine tablets for the treatment of an infection and malaria. She presented 7 days later to her psychiatrist with complaints of restlessness, tremor, palpitations, insomnia, and resurgence of obsessive thoughts. Case B is a patient who was diagnosed with first-episode psychotic depression and admitted for 10 days. Her medications on admission were fluphenazine decanoate 25 mg depot injection once, olanzapine 10 mg tablet daily, and fluoxetine 20 mg capsule daily. On discharge, ciprofloxacin 500 mg tablet every 12 hours for 5 days and fluconazole 150 mg capsule once were added to her medications for the treatment of a urinary tract infection. She reported back to the hospital a day after discharge with complaints of restlessness, "seizures," tremor, abdominal discomfort, and weight gain. Both patients were diagnosed with akathisia using ICD-10 classification and the Barnes akathisia rating scale and managed with anticholinergics, benzodiazepines, and beta blockers. Other measures employed in managing the akathisia included reducing the dose of the antipsychotic and/or switching antipsychotics. Despite these management measures, the symptoms of akathisia persisted and only resolved after 4weeks. Upon the resolution of symptoms, Case A continued treatment on olanzapine 5 mg tablet daily and fluoxetine 20 mg capsule daily while Case B continued treatment on risperidone 2 mg tablet daily and fluoxetine 20 mg capsule daily. Using Naranjo's adverse drug reaction causality assessment scale, Medscape drug interaction checker, and literature review, a possible and probable case of drug-drug-induced akathisia was made for Case A and Case B. This report is to create more awareness about psychotropic-antimicrobial-induced akathisia. The information underpins the need for health professionals to consider adverse drug-drug interactions as the probable cause of extrapyramidal side effects experienced by patients on antipsychotics.

Identifiants

pubmed: 32373382
doi: 10.1155/2020/9649483
pmc: PMC7196143
doi:

Types de publication

Case Reports

Langues

eng

Pagination

9649483

Informations de copyright

Copyright © 2020 Grace Owusu Aboagye and Daniel Ankrah.

Déclaration de conflit d'intérêts

Authors have no conflict of interest to declare.

Références

BMJ Case Rep. 2013 May 21;2013:
pubmed: 23697447
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Pharmacopsychiatry. 1998 Jul;31(4):146-8
pubmed: 9754850
Am Fam Physician. 2000 Mar 15;61(6):1745-54
pubmed: 10750880
J Psychopharmacol. 1998;12(2):192-214
pubmed: 9694033
J Psychiatr Res. 2014 Jun;53:119-24
pubmed: 24656425
Br J Psychiatry. 1989 May;154:672-6
pubmed: 2574607
J Am Pharm Assoc (2003). 2009 Mar-Apr;49(2):e28-36; quiz e37-8
pubmed: 19289334
Ther Adv Psychopharmacol. 2014 Apr;4(2):100-2
pubmed: 24688760
Indian J Psychiatry. 1999 Jul;41(3):267-8
pubmed: 21455406
CNS Spectr. 2007 Sep;12(9 Suppl 14):1-13
pubmed: 17805218
Pharmacopsychiatry. 2012 Jun;45(4):162-3
pubmed: 22290205
Am J Emerg Med. 1996 Sep;14(5):447-50
pubmed: 8765105

Auteurs

Grace Owusu Aboagye (G)

Department of Psychiatry, Korle Bu Teaching Hospital, P. O. Box KB 77, Accra, Ghana.

Daniel Ankrah (D)

Department of Pharmacy, Korle Bu Teaching Hospital, P. O. Box KB 77, Accra, Ghana.

Classifications MeSH